Community/Retail

Harnessing the current momentum and engaging with legislators is crucial for the pharmacy industry to grow and expand.

There is new guidance needed for pediatric immunizations, and pharmacists should be prepared for what's to come.

A lot of recent studies have focused on how to teach students and residents the Pharmacists' Patient Care Process (PPCP) and how pharmacists are already engaging with the PPCP.

These clear-cut guidelines help pharmacists making sure the patients are getting the right drug to set them up for success and prevent problems down the road.

Pharmacists are already doing a lot of things with the Pharmacists' Patient Care Process, but they haven't always used that language.

The future trend in managing diabetes will extend into glycemic control, weight reduction, and renal liver, for example.

Women in pharmacy must realize that what they have to offer has value, both to the business and to patients’ lives.

Finding the time to improve payer performance can be a major hurdle but designating even 30 minutes per week can make a difference.

The Pharmacist Patient Care Process provides really consistent language for pharmacists and pharmacy team members to talk about what teams are already doing.

David Pope, PharmD, CDE, the EVP of Innovation and Industry Relations at OmniSYS, discusses the FDA’s announcement updating pharmacists’ prescriptive authority for the COVID-19 antiviral Paxlovid.

Simple changes to each day can improve motivation and wellness for pharmacists.

ProAir Digihaler Inhalation Powder is indicated for the treatment or prevention of bronchospasm in those with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

In February of this year, the new statistics came out where we're at now 37 million with diabetes and 96 million with prediabetes.

Hypervitaminosis D, a condition characterized by elevated vitamin D levels, is associated with potential serious health issues, such as psychosis, abdominal pain, vomiting, pancreatitis, and renal failure.

The best thing for pharmacists to do during this time is provide unbiased, factually accurate information about this topic as a resource.

Tildrakizumab-asmn (Ilumya) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

BurnAid burn dressing provides relief for all types of minor burns.

Patient Centered Care is what should be at the heart of a pharmacist's work.

Survey results show 40% of health care leaders believe a lack of communication between prescribers and pharmacists is preventing the successful management of patients’ medications.

McKesson ideaShare 2022 is taking place in Washington, DC, from July 7 through 10.

The FDA approved a licensure request for Fluzone High-Dose Quadrivalent, Flublok Quadrivalent, and Fluzone Quadrivalent for use in the upcoming 2022-2023 flu season, providing influenza vaccination for adults 65 years of age and older.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Paxlovid treats COVID-19 in adults and children [12 years of age and older weighing at least 88 pounds (40 kg)] with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

After Bite is indicated for relieving itch from bug bites and other mild irritations.

Isotretinoin exerts dose-dependent inhibition of sebaceous gland function, thereby reducing sebum secretion, which is associated with improvement in nodular acne.

Pravastatin sodium (Pravachol) is indicated as an adjunctive therapy to diet to lower the risk of myocardial infarction, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident congenital heart disease.

In a sector that relies heavily on opacity, who knows what might be found in the government's inquiry?

Rates of influenza and associated hospitalizations demand late-season vigilance.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

The Future of Pharmacy initiative is telling the story of where the profession has been and where it is headed.